Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  1,081 results for ""OMALIZUMAB""

Your Filters

Publication : allergy
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study.

  • Authors : Pierrard G; CHU Lille, University Lille, Service de Dermatologie, Lille, France.; Bernier C

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Omalizumab*/Omalizumab*/Omalizumab*/administration & dosage ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/drug therapy

  • Source: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2448-2457. Date of Electronic Publication: 2024 Jul 26.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Periodical

The use of omalizumab in food allergy.

  • Authors : Alkotob S; Department of Pediatrics, Section of Immunology Allergy and Retrovirology, Texas Children's Hospital, Houston, Texas, USA.; Section of Allergy Immunology & Retrovirology, Baylor College of Medicine, Houston, Texas, USA.

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Food Hypersensitivity*/Food Hypersensitivity*/Food Hypersensitivity*/drug therapy ; Anti-Allergic Agents*/Anti-Allergic Agents*/Anti-Allergic Agents*/therapeutic use

  • Source: Allergy [Allergy] 2024 Oct; Vol. 79 (10), pp. 2888-2889. Date of Electronic Publication: 2024 Apr 27.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

In chronic spontaneous urticaria, increased Galectin-9 expression on basophils and eosinophils is linked to high disease activity, endotype-specific markers, and response to omalizumab treatment.

  • Authors : Ji J; Department of Dermatology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Department of Dermatology, The Second Affiliated Hospital of Soochow University, Su Zhou, China.

Subjects: Anti-Allergic Agents*/Anti-Allergic Agents*/Anti-Allergic Agents*/therapeutic use ; Anti-Allergic Agents*/Anti-Allergic Agents*/Anti-Allergic Agents*/pharmacology ; Basophils*/Basophils*/Basophils*/metabolism

  • Source: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2435-2447. Date of Electronic Publication: 2024 Jul 18.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Predicting relapse in chronic spontaneous urticaria: A retrospective cohort study evaluating omalizumab withdrawal regimens.

  • Authors : Kucharczyk A; Department of Internal Diseases, Pneumonology, Allergology and Clinical Immunology, Military Institute of Medicine - National Research Institute, Warszawa, Poland.; Marczyk K

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/drug therapy ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/diagnosis

  • Source: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2554-2557. Date of Electronic Publication: 2024 Jun 24.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment.

  • Authors : Ghazanfar MN; Department of Dermato-Venereology & Wound Healing Centre, Urticaria Center of Reference and Excellence (UCARE), Bispebjerg Hospital, Copenhagen, Denmark.; Petrosius V

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/drug therapy ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/blood

  • Source: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2547-2550. Date of Electronic Publication: 2024 May 26.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

MMP9 and CCL18 associate with chronic urticaria while type I, IV, and VI collagens change with omalizumab treatment.

  • Authors : Bartko EA; Allergy Clinic, Department of Dermatology and Allergy, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark.; Mellergaard M

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/drug therapy ; Matrix Metalloproteinase 9*/Matrix Metalloproteinase 9*/Matrix Metalloproteinase 9*/metabolism

  • Source: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2558-2561. Date of Electronic Publication: 2024 Jul 02.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.

  • Authors : Nopsopon T; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Barrett NA

Subjects: Asthma*/Asthma*/Asthma*/drug therapy ; Asthma*/Asthma*/Asthma*/physiopathology ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: Allergy [Allergy] 2024 May; Vol. 79 (5), pp. 1195-1207. Date of Electronic Publication: 2024 Jan 02.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Lin - CD117 + CD34 + FcεRI + progenitor cells are increased in chronic spontaneous urticaria and predict clinical responsiveness to anti-IgE therapy.

  • Authors : Ridge K; UCARE Centre, Clinical and Diagnostic Immunology, St. James's Hospital, Dublin, Ireland.; Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.

Subjects: Chronic Urticaria*/Chronic Urticaria*/Chronic Urticaria*/drug therapy ; Antigens, CD34*/Antigens, CD34*/Antigens, CD34*/metabolism ; Receptors, IgE*/Receptors, IgE*/Receptors, IgE*/metabolism

  • Source: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2423-2434. Date of Electronic Publication: 2024 Apr 17.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3 + Treg generation.

Subjects: Hypersensitivity, Immediate* ; Omalizumab*/Omalizumab*/Omalizumab*/pharmacology ; Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use

  • Source: Allergy [Allergy] 2023 Apr; Vol. 78 (4), pp. 1060-1072. Date of Electronic Publication: 2022 Nov 12.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Report

The impact of maternal-fetal omalizumab transfer on peanut-specific responses in an ex vivo placental perfusion model.

  • Authors : Kothari A; Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.; Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Subjects: Omalizumab*/Omalizumab*/Omalizumab*/therapeutic use ; Peanut Hypersensitivity*; Female

  • Source: Allergy [Allergy] 2022 Dec; Vol. 77 (12), pp. 3684-3686. Date of Electronic Publication: 2022 Aug 14.Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  1,081 results for ""OMALIZUMAB""